DKFMA 201
Alternative Names: DKF-MA-201Latest Information Update: 22 Jul 2025
At a glance
- Originator Dongkook Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acromegaly
Most Recent Events
- 14 Jul 2025 Preclinical trials in Acromegaly in South Korea (unspecified route), before July 2025 (Dongkook pharmaceuticals pipeline, July 2025)